ScholarLens Back to search
2018•Endocrine AbstractsRequires access

Safety and efficacy of long-acting Pasireotide monotherapy in acromegalic patients treated with a combination of first-generation somatostatin analogs and cabergoline or pegvisomant

Hélène Lasolle, Amandine Ferrière, Marie Laure Nunes, Magalie Haissaguerre, Antoine Tabarin

Open publisher page 0 citations

Abstract

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

About this research paper

What this paper is about

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Key concepts: Cabergoline, Pegvisomant, Pasireotide, Acromegaly, Medicine, Somatostatin, Octreotide, Pharmacology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Safety and efficacy of long-acting Pasireotide monotherapy in acromegalic patients treated with a combination of first-generation somatostatin analogs and cabergoline or pegvisomant — Research Paper | ScholarLens